search
Back to results

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

Primary Purpose

Healthy Participants

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
JZP441
Placebo
Sponsored by
Jazz Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Participants focused on measuring Healthy Participants, JZP441

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Is 18 to 50 years of age inclusive, at the time of signing the informed consent Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac/blood pressure monitoring. Exclusion Criteria: History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that, in the investigator opinion, may interfere with absorption, distribution, metabolism, or excretion of drugs Presence of renal impairment or calculated eGFR < 80 mL/min/1.73 m^2. Triplicate 12-lead ECG demonstrating a mean QTcF > 450 msec for males and > 470 msec for females or any other clinically significant ECG abnormality per investigator assessment prior to dose of study intervention Presence or history of significant cardiovascular disease including (but not limited to): myocardial infarction, uncontrolled hypertension, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (at Screening or baseline consistent with protocol specifications), angina pectoris, clinically significant arrhythmias, clinically significant valvular heart disease, history of any revascularization procedures or second or third degree heart block with/without a pacemaker, heart failure, or family history of Torsades de Pointes Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode; history of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months) History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or clinically significant psychiatric disorders, including other psychotic disorders History (within past 2 years at Screening) or presence of substance use disorder (including alcohol) or seeking treatment for alcohol or substance abuse related disorder History of seizure disorder or a physical condition that would increase seizure risk History of head trauma or concussions that are deemed clinically significant by the investigator Have used tobacco products or products for smoking cessation within 90 days before screening, including nicotine-containing products, or history of significant use of tobacco (> 10 cigarettes or equivalent per day) within 1 year before Screening, or unwilling to refrain from nicotine-containing products for the duration of the study Participants who are taking a concomitant medication or supplement that lowers seizure threshold (eg, kratom) Participants who have recently (< 2 weeks) discontinued a drug or supplement for which discontinuation would lower seizure threshold (eg, benzodiazepine medication) Participation in a previous JZP441 clinical study Positive alcohol test or urine drug screen (including cannabinoids and cotinine) at Screening or at any point throughout the duration of the study Presence at Screening of HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody, or a clinical history of these infections History of clinically significant acute or chronic insomnia within the last 5 years

Sites / Locations

  • Clinical Site 1Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

JZP441

Placebo

Arm Description

Healthy participants who will be randomized to receive an oral dose of JZP441.

Healthy participants who will be randomized to receive placebo.

Outcomes

Primary Outcome Measures

Number of Participants With Treatment-emergent Adverse Events
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441
Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP441
Time to maximum plasma concentration (Tmax), time of maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Tmax1), and time of maximum observed plasma concentration post second dose during the 24-hour dosing interval (Tmax2), and time of last quantifiable concentration (Tlast) will be assessed.
Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2) of JZP441
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP441
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC0-last), and area under the concentration-time curve from time zero extrapolated to infinity (AUC∞) will be assessed.
Pharmacokinetic Parameter Apparent Oral Clearance (CL/F) of JZP441
Pharmacokinetic Parameter Apparent Volume of Distribution (Vz/F) of JZP441
Pharmacokinetic Parameter Accumulation Ratio of JZP441
Accumulation ratio (Cmax) and accumulation ratio (AUC) will be assessed.
Dose Proportionality of JZP441 for Maximum Concentration (Cmax)
Dose proportionality of maximum concentration (Cmax), maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Cmax1), and maximum observed plasma concentration post second dose during the 24-hour dosing interval (Cmax2) will be assessed.
Dose Proportionality of JZP441 for Area Under the Concentration-Time Curve (AUC)
Dose proportionality of area under the concentration-time curve from 0 to 24 hours (AUC[0-24]) will be assessed.

Secondary Outcome Measures

Full Information

First Posted
January 31, 2023
Last Updated
June 16, 2023
Sponsor
Jazz Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT05720494
Brief Title
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants
Official Title
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of JZP441 in Healthy Adult Participants: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 26, 2023 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jazz Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Treatments for narcolepsy and hypersomnolence disorders should have good oral bioavailability and brain penetration properties. JZP441 has demonstrated wake-promoting efficacy and anticataplectic activity in nonclinical studies and may represent a novel approach for these patients.
Detailed Description
This Phase 1, double-blind, randomized, placebo-controlled, parallel group study is designed to characterize the safety, tolerability, and PK of multiple ascending doses of JZP441 for up to 4 weeks in healthy adult participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Participants
Keywords
Healthy Participants, JZP441

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
98 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
JZP441
Arm Type
Experimental
Arm Description
Healthy participants who will be randomized to receive an oral dose of JZP441.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Healthy participants who will be randomized to receive placebo.
Intervention Type
Drug
Intervention Name(s)
JZP441
Intervention Description
Oral study drug administered for up to 4 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral placebo administered for up to 4 weeks
Primary Outcome Measure Information:
Title
Number of Participants With Treatment-emergent Adverse Events
Time Frame
Day 1 up until 38 days after last dose of study drug, up to approximately 2 months
Title
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP441
Description
Time to maximum plasma concentration (Tmax), time of maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Tmax1), and time of maximum observed plasma concentration post second dose during the 24-hour dosing interval (Tmax2), and time of last quantifiable concentration (Tlast) will be assessed.
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2) of JZP441
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP441
Description
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC0-last), and area under the concentration-time curve from time zero extrapolated to infinity (AUC∞) will be assessed.
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Apparent Oral Clearance (CL/F) of JZP441
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Apparent Volume of Distribution (Vz/F) of JZP441
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Pharmacokinetic Parameter Accumulation Ratio of JZP441
Description
Accumulation ratio (Cmax) and accumulation ratio (AUC) will be assessed.
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Dose Proportionality of JZP441 for Maximum Concentration (Cmax)
Description
Dose proportionality of maximum concentration (Cmax), maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Cmax1), and maximum observed plasma concentration post second dose during the 24-hour dosing interval (Cmax2) will be assessed.
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28
Title
Dose Proportionality of JZP441 for Area Under the Concentration-Time Curve (AUC)
Description
Dose proportionality of area under the concentration-time curve from 0 to 24 hours (AUC[0-24]) will be assessed.
Time Frame
Pre-dose and multiple post-dose timepoints, up to Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Is 18 to 50 years of age inclusive, at the time of signing the informed consent Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac/blood pressure monitoring. Exclusion Criteria: History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that, in the investigator opinion, may interfere with absorption, distribution, metabolism, or excretion of drugs Presence of renal impairment or calculated eGFR < 80 mL/min/1.73 m^2. Triplicate 12-lead ECG demonstrating a mean QTcF > 450 msec for males and > 470 msec for females or any other clinically significant ECG abnormality per investigator assessment prior to dose of study intervention Presence or history of significant cardiovascular disease including (but not limited to): myocardial infarction, uncontrolled hypertension, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (at Screening or baseline consistent with protocol specifications), angina pectoris, clinically significant arrhythmias, clinically significant valvular heart disease, history of any revascularization procedures or second or third degree heart block with/without a pacemaker, heart failure, or family history of Torsades de Pointes Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode; history of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months) History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or clinically significant psychiatric disorders, including other psychotic disorders History (within past 2 years at Screening) or presence of substance use disorder (including alcohol) or seeking treatment for alcohol or substance abuse related disorder History of seizure disorder or a physical condition that would increase seizure risk History of head trauma or concussions that are deemed clinically significant by the investigator Have used tobacco products or products for smoking cessation within 90 days before screening, including nicotine-containing products, or history of significant use of tobacco (> 10 cigarettes or equivalent per day) within 1 year before Screening, or unwilling to refrain from nicotine-containing products for the duration of the study Participants who are taking a concomitant medication or supplement that lowers seizure threshold (eg, kratom) Participants who have recently (< 2 weeks) discontinued a drug or supplement for which discontinuation would lower seizure threshold (eg, benzodiazepine medication) Participation in a previous JZP441 clinical study Positive alcohol test or urine drug screen (including cannabinoids and cotinine) at Screening or at any point throughout the duration of the study Presence at Screening of HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody, or a clinical history of these infections History of clinically significant acute or chronic insomnia within the last 5 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Trial Disclosure & Transparency
Phone
215-832-3750
Email
ClinicalTrialDisclosure@JazzPharma.com
Facility Information:
Facility Name
Clinical Site 1
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

We'll reach out to this number within 24 hrs